Health Catalyst, Inc. (NASDAQ:HCAT) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) by 21.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 998,843 shares of the company’s stock after buying an additional 174,954 shares during the quarter. Victory Capital Management Inc. owned 1.85% of Health Catalyst worth $26,100,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in shares of Health Catalyst by 0.8% in the 4th quarter. Rhumbline Advisers now owns 49,095 shares of the company’s stock valued at $1,945,000 after purchasing an additional 409 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Health Catalyst by 3.7% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 14,024 shares of the company’s stock valued at $556,000 after purchasing an additional 499 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Health Catalyst by 2.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 22,519 shares of the company’s stock valued at $892,000 after purchasing an additional 525 shares in the last quarter. UMB Bank N A MO acquired a new stake in shares of Health Catalyst in the 4th quarter valued at $30,000. Finally, Arizona State Retirement System raised its holdings in shares of Health Catalyst by 12.9% in the 4th quarter. Arizona State Retirement System now owns 11,633 shares of the company’s stock valued at $461,000 after purchasing an additional 1,325 shares in the last quarter. 97.53% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Stock Performance

Shares of Health Catalyst stock opened at $17.90 on Thursday. The company has a market capitalization of $969.91 million, a P/E ratio of -5.77 and a beta of 1.14. The company’s fifty day moving average is $15.24 and its two-hundred day moving average is $20.77. Health Catalyst, Inc. has a 1 year low of $11.25 and a 1 year high of $59.50.

Health Catalyst (NASDAQ:HCAT – Get Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.03. The business had revenue of $68.09 million for the quarter, compared to the consensus estimate of $66.01 million. Health Catalyst had a negative net margin of 57.95% and a negative return on equity of 19.88%. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. As a group, equities analysts expect that Health Catalyst, Inc. will post -1.83 earnings per share for the current year.

Insider Activity

In other news, insider Linda Llewelyn sold 1,860 shares of Health Catalyst stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $15.87, for a total value of $29,518.20. Following the sale, the insider now owns 60,173 shares of the company’s stock, valued at $954,945.51. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, General Counsel Daniel H. Orenstein sold 2,838 shares of the firm’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $14.85, for a total value of $42,144.30. Following the completion of the sale, the general counsel now owns 103,671 shares in the company, valued at $1,539,514.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Linda Llewelyn sold 1,860 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $15.87, for a total transaction of $29,518.20. Following the completion of the sale, the insider now owns 60,173 shares of the company’s stock, valued at approximately $954,945.51. The disclosure for this sale can be found here. Insiders have sold a total of 6,255 shares of company stock valued at $93,877 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on HCAT shares. BTIG Research cut their price target on shares of Health Catalyst from $35.00 to $25.00 in a research note on Wednesday, July 27th. Citigroup cut their price target on shares of Health Catalyst from $45.00 to $25.00 in a research note on Wednesday, May 11th. Piper Sandler cut their price target on shares of Health Catalyst from $38.00 to $21.00 in a research note on Wednesday, May 11th. Royal Bank of Canada cut their price target on shares of Health Catalyst from $35.00 to $19.00 in a research note on Wednesday, May 11th. Finally, The Goldman Sachs Group cut their price target on shares of Health Catalyst from $42.00 to $37.00 and set a “buy” rating on the stock in a research note on Thursday, May 26th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $33.17.

About Health Catalyst

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Featured Articles

• Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
• Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
• There Are Different Types of Stock To Invest In
• PayPal Continues To Struggle As Competition Increases
• Is Starbucks Shooting For The Moon? 
• Two High-Yield Deep-Values You Shouldn’t Ignore 

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating).

Want More Great Investing Ideas?